Literature DB >> 32739887

BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair.

Shannon M Matulis1, Lawrence H Boise1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32739887      PMCID： PMC7395263          DOI： 10.3324/haematol.2020.253591

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

Review 1.  Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authors:  Matthew S Davids; Anthony Letai
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

3.  Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authors:  Triona Ni Chonghaile; Kristopher A Sarosiek; Thanh-Trang Vo; Jeremy A Ryan; Anupama Tammareddi; Victoria Del Gaizo Moore; Jing Deng; Kenneth C Anderson; Paul Richardson; Yu-Tzu Tai; Constantine S Mitsiades; Ursula A Matulonis; Ronny Drapkin; Richard Stone; Daniel J Deangelo; David J McConkey; Stephen E Sallan; Lewis Silverman; Michelle S Hirsch; Daniel Ruben Carrasco; Anthony Letai
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

4.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Authors:  Andrew D Zelenetz; Gilles Salles; Kylie D Mason; Carla Casulo; Steven Le Gouill; Laurie H Sehn; Herve Tilly; Guillaume Cartron; Martine E D Chamuleau; Andre Goy; Constantine S Tam; Pieternella J Lugtenburg; Adam M Petrich; Arijit Sinha; Divya Samineni; Sylvia Herter; Ellen Ingalla; Edith Szafer-Glusman; Christian Klein; Deepak Sampath; Martin Kornacker; Mehrdad Mobasher; Franck Morschhauser
Journal:  Blood       Date:  2019-03-08       Impact factor: 22.113

5.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Authors:  Alejo A Morales; Metin Kurtoglu; Shannon M Matulis; Jiangxia Liu; David Siefker; Delia M Gutman; Jonathan L Kaufman; Kelvin P Lee; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

6.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

7.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

Review 8.  The BCL-2 family reunion.

Authors:  Jerry E Chipuk; Tudor Moldoveanu; Fabien Llambi; Melissa J Parsons; Douglas R Green
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

9.  Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.

Authors:  Clare M Adams; Ramkrishna Mitra; Jerald Z Gong; Christine M Eischen
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

Review 10.  Targeting the Bcl-2 Family in B Cell Lymphoma.

Authors:  Clare M Adams; Sean Clark-Garvey; Pierluigi Porcu; Christine M Eischen
Journal:  Front Oncol       Date:  2019-01-08       Impact factor: 6.244
View more
  2 in total

Review 1.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 2.  Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.

Authors:  Aleksandra Kusowska; Matylda Kubacz; Marta Krawczyk; Aleksander Slusarczyk; Magdalena Winiarska; Malgorzata Bobrowicz
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.